Search

n8n RCE Vulnerability CVE-2025-68613

CISA has added CVE-2025-68613, a critical Remote Code Execution vulnerability in n8n's workflow evaluation system, to its Known Exploited Vulnerabilities (KEV) catalog. The vulnerability affects versions prior to 1.120.4, 1.121.1, and 1.122.0 and allows authenticated attackers to execute arbitrary code.

Ivanti EPM Authentication Bypass Vulnerability

CISA has added a vulnerability (CVE-2026-1603) in Ivanti Endpoint Manager (EPM) to its Known Exploited Vulnerabilities (KEV) catalog. The vulnerability, an authentication bypass allowing credential data leakage, affects versions before 2024 SU5.

SolarWinds Web Help Desk RCE Vulnerability CVE-2025-26399

CISA has added CVE-2025-26399, a critical remote code execution vulnerability in SolarWinds Web Help Desk, to its Known Exploited Vulnerabilities (KEV) catalog. The vulnerability affects versions 12.8.7 and below and allows unauthenticated attackers to run commands on the host machine.

VMware Workspace ONE UEM SSRF Vulnerability CVE-2021-22054

CISA has added VMware Workspace ONE UEM console versions to the Known Exploited Vulnerabilities (KEV) catalog due to an SSRF vulnerability (CVE-2021-22054). This vulnerability may allow a malicious actor to gain access to sensitive information.

Apple Use-After-Free Vulnerability Fixed in iOS/iPadOS 17

CISA has added a use-after-free vulnerability (CVE-2023-41974) affecting Apple iOS and iPadOS to its Known Exploited Vulnerabilities (KEV) catalog. The vulnerability, which could allow an app to execute arbitrary code with kernel privileges, has been fixed by Apple in iOS 17, iPadOS 17, iOS 15.8.7, and iPadOS 15.8.7.

WHO Expert Committee on Pharmaceutical Preparations Meeting

The World Health Organization (WHO) announced the Sixtieth meeting of the Expert Committee on Specifications for Pharmaceutical Preparations, scheduled for October 12-16, 2026. This committee advises the Director-General on medicine quality assurance and the maintenance of The International Pharmacopoeia.

FDA Drug Shortage Update

The FDA has updated its list of current and resolved drug shortages. The notice indicates 56 drugs are currently in shortage, 45 have been resolved, and 11 have been discontinued. This update provides a snapshot of the ongoing drug supply situation.

FDA Report on Drug Shortage Prevention Efforts

The FDA has released its annual report to Congress detailing efforts in calendar year 2024 to prevent and mitigate drug shortages. The report highlights successful interventions that prevented 283 potential shortages, with only 15 new shortages identified.

FDA Approves 5 New Novel Drugs in 2026

The FDA has announced the approval of five new novel drugs in 2026 for various medical conditions. These approvals include treatments for achondroplasia, hyperarginemia, schizophrenia, bipolar disorder, atopic dermatitis, and Menkes disease. The agency updated its list of novel drug therapy approvals.

FDA Novel Drug Approvals 2024

The FDA's Center for Drug Evaluation and Research (CDER) approved 50 novel drugs in 2024, representing new molecular entities never before marketed in the U.S. This notice provides a list of these approvals and links to detailed reports and drug information.